Viatris Inc. (VTRS)

Wall Street analysts covering Viatris Inc. currently rate the stock a Buy on average, with a mean 12-month price target of $18.50 — +14.9% versus the last price of $16.10. Targets reflect analyst opinion, not a guarantee.

9 members of Congress have disclosed trading VTRS — 3 purchases and 7 sales worth an estimated $96,000. Most recent disclosure: Apr 8, 2025.

VTRS's own executives and directors have made 0 open-market purchases ($0) and 1 sale ($809,784) in the last 90 days, per SEC Form 4 filings. Most recent: Jun 25, 2026.

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Company website ↗

• ROE (-2.75%) — how efficiently the company turns shareholders' money into profit. Negative means it's currently losing money on that equity.
• Profit margin (-2.79%) — of every $1 in sales, this is what's left as profit after all costs.
• Dividend yield (2.98%) — the cash payout you'd earn per year as a % of the share price, on top of any price gains.